FMT for recurrent Clostridium difficile infection

Phase 2, open-label, single-arm trial in Clostridium difficile infection (CDI), sponsored by OpenBiome. Primary endpoints: Short-term Safety of FMT as Measured by Absence or Presence of Related Serious Adverse Events at 6 weeks and Long-term Safety of FMT as Measured by Absence or Presence of Adverse Events at 1 year. Started Mar 2015; status: terminated.